| ES2567047T3 (es)* | 2008-12-23 | 2016-04-19 | Abbvie Inc. | Derivados de pirimidina anti-virales |
| RU2505539C2 (ru) | 2008-12-23 | 2014-01-27 | Эбботт Лэборетриз | Антивирусные соединения |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9278922B2 (en)* | 2009-04-15 | 2016-03-08 | Abbvie Inc. | Anti-viral compounds |
| AP3622A (en) | 2009-05-13 | 2016-03-02 | Gilead Sciences Inc | Antiviral compounds |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UY32699A (es)* | 2009-06-11 | 2010-12-31 | Abbott Lab | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| CN102656160A (zh) | 2009-07-16 | 2012-09-05 | 顶点制药公司 | 用于治疗或预防黄病毒感染的苯并咪唑类似物 |
| WO2011028596A1 (en) | 2009-09-04 | 2011-03-10 | Glaxosmithkline Llc | Chemical compounds |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201136942A (en) | 2009-12-18 | 2011-11-01 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
| CN104530079B (zh)* | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2013522375A (ja) | 2010-03-24 | 2013-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染を処置または予防するためのアナログ |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| EA025151B1 (ru) | 2010-10-26 | 2016-11-30 | Пресидио Фармасьютикалс, Инк. | Ингибиторы вируса гепатита с |
| JP5891235B2 (ja)* | 2010-11-04 | 2016-03-22 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｃ型肝炎ウイルスの新規阻害剤 |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| NZ623396A (en) | 2011-09-16 | 2016-07-29 | Gilead Pharmasset Llc | Methods for treating hcv |
| WO2013067267A1 (en) | 2011-11-03 | 2013-05-10 | Theravance, Inc. | Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9066944B2 (en) | 2012-04-25 | 2015-06-30 | Theravance Biopharma R&D Ip, Llc | Hepatitis C virus inhibitors |
| ME02682B (me) | 2012-04-25 | 2017-06-20 | Theravance Biopharma R&D Ip Llc | Jedinjenja piperazina-piperidina kao inhibitori virusa hepatitisa c |
| WO2013165796A1 (en)* | 2012-05-03 | 2013-11-07 | Theravance, Inc. | Crystalline form of a pyridyl-piperazinyl hepatitis c virus inhibitor |
| KR20200060782A (ko) | 2013-01-31 | 2020-06-01 | 길리애드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| GB201305376D0 (en)* | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US20190151324A1 (en) | 2016-06-23 | 2019-05-23 | University Of Maryland, Baltimore | NON-CATALYTIC SUBSTRATE-SELECTIVE P38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF |
| CN108794454B (zh)* | 2017-04-27 | 2023-08-15 | 广东东阳光药业股份有限公司 | 一种咪唑环化合物的制备方法 |
| CN112409336B (zh)* | 2017-11-27 | 2021-09-14 | 常州寅盛药业有限公司 | 适于工业化生产的达卡他韦起始原料的合成方法 |
| CN113395963B (zh) | 2018-12-07 | 2024-06-25 | 马里兰大学巴尔的摩分校 | 非ATP/催化位点p38丝裂原活化蛋白激酶抑制剂 |
| CN116406355A (zh) | 2020-05-18 | 2023-07-07 | Gen1E生命科学公司 | P38α促分裂原活化蛋白激酶抑制剂 |
| JP2023546835A (ja) | 2020-10-29 | 2023-11-08 | ジーニー ライフサイエンシズ インコーポレイテッド | 結晶性５－（ジメチルアミノ）－ｎ－（４－（モルホリノメチル）フェニル）ナフタレン－１－スルホンアミド二塩酸塩二水和物 |
| CN117120422A (zh) | 2021-03-23 | 2023-11-24 | Gen1E生命科学公司 | 取代的萘基P38α丝裂原活化的蛋白激酶抑制剂 |
| WO2022246109A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |